natgillin/translations-raw huggingface dataset:
Frequencies are defined as: - Very common ( 1/10) - Common ( 1/100 to < 1/10) - Uncommon ( 1/1,000 to < 1/100) - Rare ( 1/10,000 to < 1/1,000) - Very rare (< 1/10,000) - Not known (cannot be estimated from the available data) 
Neželeni učinki, o katerih so poročali večkrat (> 0,5%) kot pri placebu in več kot enkrat pri bolnikih, ki so prejemali pioglitazon v dvojno slepih študijah, so našteti spodaj, in sicer po razredih organskih sistemov in absolutni pogostnosti, kot je priporočeno po MedDRA. Pogostnosti so določene kot: - zelo pogosti (≥ 1/10), - pogosti (≥ 1/100 do < 1/10), - občasni (≥ 1/1.000 do < 1/100), - redki (≥ 1/10.000 do < 1/1.000), - zelo redki (< 1/10.000), - neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Paglitaz tablets should be used every day to work properly. 
Za pravilno delovanje je potrebno zdravilo Paglitaz jemati vsak dan.
Environmental Risk Assessment (ERA) : no environmental impact is anticipated from the clinical use of pioglitazone. 
Ocena tveganja za okolje: ob klinični uporabi pioglitazona ni pričakovati vpliva na okolje.
The other side effects that have been experienced by some patients when Paglitaz is taken with other antidiabetic medicines are: 
Pri nekaterih bolnikih, ki so jemali zdravilo Paglitaz skupaj z drugimi antidiabetičnimi zdravili, so se pojavili naslednji drugi neželeni učinki:
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Paglitaz. 
Rak mehurja se lahko pojavi občasno (pojavijo se lahko pri največ 1 od 100 bolnikov) pri bolnikih, ki jemljejo zdravilo Paglitaz.
How to take Paglitaz 
Kako jemati zdravilo Paglitaz
What Paglitaz contains - The active substance is pioglitazone. 
Kaj vsebuje zdravilo Paglitaz - Zdravilna učinkovina je pioglitazon.
Allergic reactions have been reported (frequency not known) in patients taking Paglitaz. 
Pri bolnikih, ki jemljejo zdravilo Paglitaz, so poročali o alergijskih reakcijah (pogostnost ni znana).
Heart failure has been experienced commonly (may affect up to 1 in 10 people) in patients taking Paglitaz in combination with insulin. 
Odpoved srca je bila pogosto (pojavijo se lahko pri največ 1 od 10 bolnikov) ugotovljena pri bolnikih, ki so jemali Paglitaz v kombinaciji z insulinom.
Neoplasms benign, malignant and unspecified (including cysts and polyps) bladder cancer uncommon uncommon uncommon uncommon uncommon Respiratory, thoracic and mediastinal disorders dyspnoea common 
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi) rak mehurja občasni občasni občasni
The risk of fractures should be considered in the long term care of patients treated with pioglitazone. 
Pri dolgoročnem zdravljenju bolnikov s pioglitazonom je potrebno upoštevati tveganje za zlome.
as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin; - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea; 
- s sulfonilsečnino, le pri odraslih bolnikih, ki ne prenašajo metformina ali je metformin pri njih kontraindiciran, z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku kot trojno peroralno zdravljenje v kombinaciji: - z metforminom in s sulfonilsečnino pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) z nezadostnim nadzorom glikemije kljub dvojnemu peroralnemu zdravljenju.
Talk to your doctor before stopping this treatment. 
Zdravnik vam bo svetoval, da prenehate z jemanjem tega zdravila.
Investigations weight increased common common common common common blood creatine phospho-kinase increased common increased lactic dehydro-genase uncommon 
Preiskave povečanje telesne mase povišana vrednost kreatin fosfokinaze v krvi povišana vrednost laktatne dehidrogenaze občasni zvišana vrednost alaninaminotransferaze neznana neznana neznana
Paglitaz may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control in blood sugar. 
Zdravilo Paglitaz lahko uporabljamo samo pri bolnikih, ki ne morejo jemati metformina, in ko zdravljenje z dieto in telesno vadbo ni uspešno pri nadzoru krvnega sladkorja.
Blurred vision due to swelling (or fluid) at the back of the eye (frequency not known) has also been reported in patients taking Paglitaz. 
Bolniki, ki so jemali Paglitaz, so poročali tudi o zamegljenem vidu zaradi otekanja (ali tekočine) očesnega ozadja (pogostnost ni poznana).
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin oedema very common fatigue uncommon 
Kombinacija z metforminom s sulfonilsečnino z metforminom in sulfonilsečnino z insulinom edem zelo pogosti utrujenost občasni
as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. 
kot dvojno peroralno zdravljenje v kombinaciji: - z metforminom pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku monoterapije z
The other side effects that have been experienced by some patients taking Paglitaz are: 
Pri nekaterih bolnikih, ki so jemali zdravilo Paglitaz, so se pojavili drugi neželeni učinki:
What Paglitaz looks like and contents of the pack White to almost white round tablets with bevelled edges (diameter 8.0 mm). 
Izgled zdravila Paglitaz in vsebina pakiranja Bele do skoraj bele, okrogle tablete s prirezanimi robovi (premer 8,0 mm).
14 tablets: EU/1/11/721/001 28 tablets: EU/1/11/721/002 30 tablets: EU/1/11/721/003 56 tablets: EU/1/11/721/004 60 tablets: EU/1/11/721/005 90 tablets: EU/1/11/721/006 98 tablets: EU/1/11/721/007 
14 tablet: EU/1/11/721/001 28 tablet: EU/1/11/721/002 30 tablet: EU/1/11/721/003 56 tablet: EU/1/11/721/004 60 tablet: EU/1/11/721/005 90 tablet: EU/1/11/721/006 98 tablet: EU/1/11/721/007
14 tablets: EU/1/11/721/015 28 tablets: EU/1/11/721/016 30 tablets: EU/1/11/721/017 56 tablets: EU/1/11/721/018 60 tablets: EU/1/11/721/019 90 tablets: EU/1/11/721/020 98 tablets: EU/1/11/721/021 
14 tablet: EU/1/11/721/015 28 tablet: EU/1/11/721/016 30 tablet: EU/1/11/721/017 56 tablet: EU/1/11/721/018 60 tablet: EU/1/11/721/019 90 tablet: EU/1/11/721/020 98 tablet: EU/1/11/721/021
14 tablets: EU/1/11/721/008 28 tablets: EU/1/11/721/009 30 tablets: EU/1/11/721/010 56 tablets: EU/1/11/721/011 60 tablets: EU/1/11/721/012 90 tablets: EU/1/11/721/013 98 tablets: EU/1/11/721/014 
14 tablet: EU/1/11/721/008 28 tablet: EU/1/11/721/009 30 tablet: EU/1/11/721/010 56 tablet: EU/1/11/721/011 60 tablet: EU/1/11/721/012 90 tablet: EU/1/11/721/013 98 tablet: EU/1/11/721/014
What Paglitaz looks like and contents of the pack White to almost white round tablets with bevelled edges and with engraved "45" on one side of tablet (diameter 10.0 mm). 
Izgled zdravila Paglitaz in vsebina pakiranja Bele do skoraj bele, okrogle tablete s prirezanimi robovi in z oznako ‘45' na eni strani (premer 10,0 mm).
What Paglitaz looks like and contents of the pack White to almost white round tablets with bevelled edges and with engraved "15" on one side of tablet (diameter 7.0 mm). 
Izgled zdravila Paglitaz in vsebina pakiranja Bele do skoraj bele, okrogle tablete s prirezanimi robovi in z oznako ‘15' na eni strani (premer 7,0 mm).
How to store Paglitaz 
Shranjevanje zdravila Paglitaz
Paglitaz tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. 
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
- if you have a special type of diabetic eye disease called macular oedema (swelling of the back of the eye). 
Če jemljete protivnetna zdravila, ki tudi lahko povzročijo zastajanje tekočine v telesu in otekanje, morate o tem prav tako obvestiti svojega zdravnika; - če imate poseben tip diabetične očesne bolezni, imenovane makularni edem (oteklina očesnega ozadja);
Alanine aminotransferase increased not known not known not known not known not known 
Očesne bolezni motnje vida občasni makularni edem neznana neznana neznana neznana neznana
Localised swelling (oedema) has also been experienced very commonly in patients taking Paglitaz in combination with insulin. 
Pri bolnikih, ki so jemali Paglitaz v kombinaciji z insulinom, je bilo zelo pogosto ugotovljeno lokalno otekanje (edemi).
If you experience this symptom for the first time, talk to your 
Če ste prvič opazili ta simptom, se posvetujte s svojim zdravnikom kakor hitro mogoče.
Paglitaz contains lactose monohydrate 
Zdravilo Paglitaz vsebuje laktozo.
If you stop using Paglitaz tablets, your blood sugar may go up. 
Če ste prenehali jemati zdravilo Paglitaz, se vam lahko raven krvnega sladkorja zviša, zato se posvetujte z zdravnikom, preden prenehate s tem zdravljenjem.
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Paglitaz. 
Zdravilo Paglitaz vsebuje laktozo monohidrat Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
Do not take Paglitaz: - if you are hypersensitive (allergic) to pioglitazone or any of the other ingredients of this medicine (listed in section 6). 
Pioglitazon je kontraindiciran pri bolnikih: - s preobčutljivostjo na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju
Broken bones have been reported commonly (may affect up to 1 in 10 people) in women patients taking Paglitaz. 
Pri bolnicah, ki so jemale Paglitaz, je bil pogosto (pojavljajo se lahko pri največ 1 od 10 bolnic) opažen zlom kosti.
These or other signs may mean the person might need treatment in hospital. 
Ti ali drugi znaki lahko pomenijo, da oseba potrebuje zdravljenje v bolnišnici.
However, you should seek immediate treatment in any event. 
Vendar morate takojšnje zdravljenje poiskati v vsakem primeru.
Most people fully recover from the illness. 
Večina ljudi si od bolezni povsem opomore.
Date of first authorisation: 02 February 2005 Date of latest renewal: 10 December 2009 
Datum pridobitve dovoljenja za promet: 02. februar 2005 Datum zadnjega podaljšanja dovoljenja za promet: 10. december 2009
Such reactions may occur before leaving the doctor's surgery. 
Takšne reakcij se lahko pojavijo, še preden zapustite zdravnikovo ordinacijo.
• This means they can still infect other people and are known as virus “carriers”. 
• To pomeni, da še vedno lahko okužijo druge in jih imenujemo "nosilci virusa".
If this happens, take special care while driving or using any tools or machines. 
Če se vam to zgodi, bodite posebno pozorni pri vožnji in uporabi orodij ali strojev.
If not, you may not be fully protected against the disease. 
V nasprotnem primeru je možno, da pred boleznijo niste popolnoma zaščiteni.
Your doctor will make sure that the vaccines are injected into different parts of the body. 
Zdravnik bo poskrbel, da vam bodo cepivi injicirali v različne dele telesa.
• The hepatitis B virus stays in the body of some people all through their lives. 
• Virus hepatitisa B ostane v telesu nekaterih ljudi vse njihovo življenje.
• Signs may not be seen for 6 weeks to 6 months after infection. 
• Znaki se lahko pojavijo šele 6 tednov do 6 mesecev po okužbi.
These antibodies will protect you against the disease. 
Ta protitelesa vas bodo ščitila pred boleznijo.
A minor infection such as a cold should not be a problem, but talk to your doctor first. 
Blažja okužba, npr. prehlad, ne bi smela biti težava, vendar se vseeno najprej pogovorite z zdravnikom.
• Some people with hepatitis B do not look or feel ill - they do not have any signs of illness. 
• Nekatere osebe s hepatitisom B niso videti bolne in se ne počutijo bolne - takšne osebe nimajo nobenih znakov bolezni.
The vaccine can be given after you have recovered. 
Cepivo lahko dobite, ko okrevate.
Their frequency is defined using the conventions listed below: 
Njihova pogostnost je opredeljena upoštevaje spodaj navedeni dogovor:
• loss of feeling or problems moving some parts of your body 
• izguba občutka ali težave s premikanjem nekaterih delov telesa,
However, solicited general symptoms were observed with similar frequencies in both groups. 
Splošni spontani simptomi so bili opaženi s podobno pogostnostjo v obeh skupinah.
• infection caused by a virus 
• okužba, ki jo povzroči virus,
• The doctor or nurse will tell you when you should come back for the next injections. 
• Zdravnik ali medicinska sestra vam bosta povedala, kdaj morate priti po naslednje injekcije.
Read all of this leaflet carefully before you receive this vaccine because it contains important information for you. 
Preden prejmete to cepivo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
What is hepatitis B? 
Kaj je hepatitis B?
• allergic reactions, including anaphylactoid reactions. 
• alergijske reakcije, vključno z anafilaktoidnimi reakcijami.
Your doctor will tell you if you need any extra or “booster” injections in the future. 
Zdravnik vam po povedal, ali v prihodnosti potrebujete kakšne dodatne ali 'obnovitvene' injekcije.
Limited data on overdose are available. 
Na voljo so omejeni podatki o prevelikem odmerjanju.
The doctor or nurse will give Fendrix as an injection into your muscle. 
Zdravnik ali medicinska sestra vam bosta dala cepivo Fendrix kot injekcijo v mišico.
The safety and efficacy of Fendrix in children aged less than 15 years have not been established. 
Učinkovitost in varnost cepiva Fendrix nista ugotovljeni pri otrocih, mlajših od 15 let.
• You will have a series of four injections. 
• Prejeli boste zaporedje štirih injekcij.
• problems with the nerves of your eye (optic neuritis) 
• težave z očesnim živcem (optični nevritis),
• Store in a refrigerator (2°C - 8°C). 
• Shranjujte v hladilniku (2°C - 8°C).
It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate immune response may not be elicited. 
Lahko se pričakuje, da pri bolnikih, ki se zdravijo z imunosupresivnimi oblikami zdravljenja ali pri bolnikih z imunsko pomanjkljivostjo, zadosten imunski odziv morda ne bo dosežen.
Since intramuscular administration into the gluteal muscle could lead to a suboptimal response to the vaccine, this route should be avoided. 
Ker lahko intramuskularno dajanje cepiva v glutealno mišičnino vodi v suboptimalni odziv na cepivo, se je temu načinu dajanja potrebno izogibati.
The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule: 1 month, 2 months and 6 months from the date of the first dose. 
Osnovno cepljenje sestavljajo 4 posamezni 0,5 ml odmerki, ki so dani po naslednji shemi: 1mesec, 2 meseca in 6 mesecev po prejemu prvega odmerka.
Pharmacotherapeutic group: Vaccines, hepatitis vaccines, ATC code J07BC01. 
Farmakoterapevtska skupina: Cepiva proti virusom hepatitisa, Oznaka ATC: J07BC01
Fendrix is for adults and young people aged 15 years and above. 
Cepivo Fendrix je namenjeno za odrasle in mladostnike, stare 15 let ali več.
Immunological data 
Imunološki podatki
• As with all vaccines, a course of Fendrix cannot fully protect all people that are vaccinated. 
• Tako kot velja za vsa cepiva, ciklus cepiva Fendrix ne more povsem zaščititi vseh cepljenih oseb.
If you are pregnant or breast-feeding, think that you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this vaccine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden prejmete to cepivo.
Hepatitis B is caused by a virus which makes the liver swollen. 
Povzročitelj hepatitisa B je virus, ki povzroči oteklino jeter.
• feeling nervous 
• občutek živčnosti,
• Fendrix helps your body to produce its own protection against the virus (antibodies). 
• Cepivo Fendrix telesu pomaga ustvariti lastno zaščito proti virusu (protitelesa).
These may be local or widespread rashes that may be itchy or blistering, swelling of the eyes and face, difficulty in breathing or swallowing, a sudden drop in blood pressure and loss of consciousness. 
To so lahko lokalizirani ali razširjeni izpuščaji, ki lahko srbijo ali se razvijejo mehurji, oteklost oči in obraza, težave z dihanjem ali požiranjem, nenaden padec krvnega tlaka in izguba zavesti.
1adjuvanted by AS04C containing: - 3-O-desacyl-4'- monophosphoryl lipid A (MPL) 2 
1adjuvans AS04C, ki vsebuje: - 3-O-desacil-4'- monofosforil lipid A (MPL) 2
Before administration, the vaccine should be well shaken to obtain a slightly opaque, white suspension. 
Pred aplikacijo je potrebno cepivo dobro pretresti, da nastane rahlo motna bela suspenzija.
• if you have any known allergies • if you have had any health problems after having a vaccine in the past. 
• če ste kdaj v preteklosti imeli kakšne zdravstvene težave po cepljenjih.
In a reproductive toxicity study in animals which included post-natal follow-up until weaning (see section 5.3), no effect on the development of the pups was observed. 
V študiji škodljivih vplivov na sposobnost razmnoževanja pri živalih, v katero je bilo vključeno tudi spremljanje mladičev do odstavitve (glejte poglavje 5.3), vplivi na postnatalni razvoj psičkov niso bili opaženi.
Because of the long incubation period of hepatitis B, it is possible that subjects could have been infected before the time of immunisation. 
Zaradi dolge inkubacijske dobe hepatitisa B je možno, da so bile osebe okužene že pred cepljenjem.
Carriers of hepatitis B 
Nosilci hepatitisa B
• Experience with hepatitis B vaccine: 
• Izkušnje s cepivi proti hepatitisu B:
Contents of the pack and other information What Fendrix contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje cepivo Fendrix
What you need to know before you receive Fendrix 
Kaj morate vedeti, preden boste prejeli cepivo Fendrix
• Once you have had the first injection of Fendrix, the next injections need also to be Fendrix (not another sort of hepatitis B vaccine). 
• Ko enkrat prejmete prvo injekcijo cepiva Fendrix, morajo biti tudi naslednje injekcije cepivo Fendrix (ne kakšna druga vrsta cepiva proti hepatitisu B).
Upon storage, a fine white deposit with a clear colourless supernatant can be observed. 
Med shranjevanjem se lahko pojavi fina bela usedlina in bister brezbarven supernatant.
For any information about this medicine, please contact the local representative of the Marketing Authorisation holder. 
Za vse morebitne nadaljnje informacije o tem cepivu se lahko obrnete na predstavništvo imetnika dovoljenja za promet.
• severe headache with a stiff neck 
• hud glavobol z otrplostjo vratu,
• Carriers of the virus are likely to get serious liver problems, such as “cirrhosis” or liver cancer. 
• Pri nosilcih virusa obstaja verjetnost resnih težav z jetri, npr. ciroze ali raka jeter.
• The virus is found in body fluids such as in the vagina, blood, semen, or saliva (spit). 
• Virus se nahaja v telesnih tekočinah, npr. v nožnici, krvi, spermi ali slini (izpljunku).
The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E or other pathogens known to infect the liver. 
Cepivo ne bo preprečilo okužb z drugimi povzročitelji, kot so virus hepatitisa A, virus hepatitisa C in virus hepatitisa E, ter z drugimi patogeni, ki okužijo jetra.
What Fendrix is and what it is used for What you need to know before you receive Fendrix How Fendrix is given 
Kaj je cepivo Fendrix in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli cepivo Fendrix Kako se uporablja cepivo Fendrix
There are no data from the use of Fendrix in pregnant women. 
Ni podatkov o uporabi cepiva Fendrix pri nosečnicah.
Pharmacokinetic properties of Fendrix or MPL alone has not been studied in humans. 
Farmkokinetične lastnosti cepiva Fendrix ali samega MPL pri ljudeh niso bile raziskane.
• Suspension for injection in a prefilled syringe. 
• Suspenzija za injiciranje v napolnjeni injekcijski brizgi.
Fendrix should under no circumstances be administered intradermally or intravenously. 
Cepivo Fendrix se v nobenem primeru ne sme dajati intradermalno ali intravaskularno.
This is usually in your upper arm. 
Ponavadi bo to mišica na nadlakti.
No increase in the reactogenicity was observed after the booster vaccination with respect to the primary vaccination. 
Po obnovitvenem cepljenju ni bilo opažena povečana reaktogenost glede na osnovno cepljenje.
The most common adverse reactions reported were local reactions at the injection site. 
Neželene reakicije, o katerih so najpogosteje poročali, so bile lokalne reakcije na mestu aplikacije.
In a large double-blind randomised comparative study, healthy subjects were enrolled to receive a three dose primary course of Fendrix (N= 713) or a commercially available hepatitis B vaccine (N= 238) at 0, 1, 2 months. 
V veliko dvojno slepo randomizirano primerjalno študijo so bile vključene zdrave osebe, ki so med osnovnim cepljenjem prejele tri odmerke cepiva Fendrix (N = 713) ali komercialno dostopno cepivo proti hepatitisu (N = 238) po shemi 0, 1, 2 mesec.
As no data are available for the concomitant administration of this particular vaccine with other vaccines, an interval of 2 to 3 weeks should be respected. 
Ker podatkov o sočasnem dajanju tega in drugih cepiv ni, je pri cepljenju potrebno upoštevati presledek 2 do 3 tednov.
• The other ingredients in Fendrix are: sodium chloride, water for injections. 
• Pomožne snovi cepiva Fendrix so: natrijev klorid in voda za injekcije.
• If you miss an injection, talk to your doctor and arrange another visit. 
Če ste izpustili odmerek • Če ste izpustili injekcijo, se posvetujte z zdravnikom in se dogovorite za drug obisk pri njem.
Vaccination with Fendrix induced more transient local symptoms as compared to the comparator vaccine, with pain at the injection site being the most frequently reported solicited local symptom. 
V primerjavi s primerjalnim cepivom je cepljenje s cepivom Fendrix povzročilo bolj prehodne lokalne simptome, pri čemer so najpogosteje poročali o bolečini na mestu injiciranja kot lokalnem spontanem simptomu.
No fertility data are available. 
Plodnost Podatkov o ploodnosti ni.
As with any vaccine, a protective immune response may not be elicited in all vaccinees. 
Možno je, tako kot pri kateremkoli drugem cepivu, da se zaščitni imunski odziv ne bo pojavil pri vseh cepljenih osebah.
• Fendrix is available in packs of 1 (with or without a separate needle) and in a pack size of 10 without needles. 
• Cepivo Fendrix je na voljo v pakiranjih z 1 napolnjeno injekcijsko brizgo (z ločeno iglo ali brez nje) in v pakiranjih z 10 napolnjenimi injekcijskimi brizgami brez igel.
Some of the undesirable effects mentioned under section 4.8 may affect the ability to drive or use machines. 
Na sposobnost vožnje ali upravljanje strojev lahko vplivajo nekateri neželeni učinki, ki so navedeni v poglavju 4.8.
How Fendrix is given How the vaccine is given 
Kako uporabljati cepivo Fendrix Kako se cepivo daje
The reactogenicity profile of Fendrix in healthy subjects was generally comparable to that seen in prehaemodialysis and haemodialysis patients. 
Reaktogeni profil cepiva Fendrix pri zdravih osebah je bil na splošno primerljiv s tistim pri predhemodializnih in hemodializnih bolnikih.
Primary immunisation: 
Osnovno cepljenje:
• Fendrix is a white, milky suspension presented in a glass prefilled syringe (0.5 ml). 
• Cepivo Fendrix je bela, mlečna suspenzija v stekleni napolnjeni injekcijski brizgi (0,5 ml).